AngioDynamics (NASDAQ:ANGO) Rating Lowered to Hold at Wall Street Zen

AngioDynamics (NASDAQ:ANGO) was downgraded by stock analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a research report issued on Saturday, Wall Street Zen reports.

ANGO has been the topic of a number of other research reports. HC Wainwright increased their price target on shares of AngioDynamics from $16.00 to $19.00 and gave the stock a “buy” rating in a report on Wednesday, July 15th. Canaccord Genuity Group restated a “buy” rating and set a $20.00 price objective on shares of AngioDynamics in a research report on Friday. Zacks Research raised shares of AngioDynamics from a “strong sell” rating to a “hold” rating in a report on Monday, October 5th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of AngioDynamics in a research report on Friday, July 17th. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, AngioDynamics currently has an average rating of “Moderate Buy” and a consensus target price of $19.50.

AngioDynamics Stock Performance

Shares of NASDAQ ANGO opened at $11.52 on Friday. The business has a 50-day moving average of $15.32 and a 200-day moving average of $13.12. The firm has a market capitalization of $484.42 million, a price-to-earnings ratio of -14.77 and a beta of 0.30. AngioDynamics has a 12 month low of $9.39 and a 12 month high of $16.29.

AngioDynamics (NASDAQ:ANGO) last announced its earnings results on Thursday, October 8th. The medical instruments supplier reported ($0.04) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.07. The business had revenue of $80.92 million for the quarter, compared to the consensus estimate of $80.51 million. AngioDynamics had a negative net margin of 10.12% and a negative return on equity of 4.49%. AngioDynamics has set its FY 2027 guidance at -0.290–0.240 EPS. On average, analysts predict that AngioDynamics will post -0.25 earnings per share for the current year.

Insider Activity at AngioDynamics

In related news, SVP Warren Jr sold 23,370 shares of the firm’s stock in a transaction dated Thursday, July 30th. The stock was sold at an average price of $14.72, for a total transaction of $344,006.40. Following the transaction, the senior vice president directly owned 64,745 shares of the company’s stock, valued at approximately $953,046.40. This trade represents a 26.52% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Company insiders own 6.00% of the company’s stock.

Institutional Trading of AngioDynamics

A number of hedge funds have recently bought and sold shares of the company. Integrated Wealth Concepts LLC bought a new stake in AngioDynamics in the second quarter worth $38,000. Legal & General Group Plc purchased a new stake in AngioDynamics during the second quarter valued at about $45,000. Public Employees Retirement System of Ohio purchased a new stake in AngioDynamics during the second quarter valued at about $64,000. State of Wyoming bought a new position in shares of AngioDynamics during the second quarter valued at about $72,000. Finally, Inceptionr LLC bought a new position in shares of AngioDynamics during the first quarter valued at about $115,000. Institutional investors own 89.43% of the company’s stock.

AngioDynamics News Summary

Here are the key news stories impacting AngioDynamics this week:

• Positive Sentiment: Adjusted earnings beat expectations. AngioDynamics reported fiscal Q1 2027 adjusted EPS of a $0.04 loss, better than the $0.11 loss analysts expected. Revenue reached $80.9 million, slightly above consensus and up 6.9% year over year. Zacks earnings report
• Positive Sentiment: Med Tech growth and margins were strong. Med Tech sales rose 13.2% to $39.9 million, led by 14.7% growth in Auryon sales and 29% growth in NanoKnife sales. Gross margin expanded 410 basis points to 59.4%, while the GAAP net loss narrowed from the prior year. The company also received FDA IDE approval for a NanoKnife feasibility study in benign prostatic hyperplasia. AngioDynamics fiscal Q1 results
• Positive Sentiment: Canaccord reaffirmed its Buy rating and set a $20 price target, implying substantial potential upside from the referenced share price. Benzinga report
• Neutral Sentiment: Fiscal 2027 guidance was reiterated: revenue of $336 million to $341 million and an adjusted EPS loss of $0.24 to $0.29. The outlook remains broadly in line with analyst expectations, but it does not yet indicate a return to profitability. Seeking Alpha guidance report
• Negative Sentiment: Leadership uncertainty is weighing on sentiment. Eric Honroth will become president and CEO on November 2, succeeding Jim Clemmer. The transition adds execution risk even as operating momentum improves. CEO appointment announcement
• Negative Sentiment: Profitability and cash flow remain concerns. AngioDynamics posted a GAAP net loss of $7.1 million and used $15.3 million of operating cash during the quarter. These issues likely overshadowed the adjusted EPS and revenue beats. Reported short-interest data showing zero shares appears inconsistent and should be treated cautiously.

AngioDynamics Company Profile

AngioDynamics, Inc is a medical device company that develops, manufactures and markets minimally invasive products for use in vascular disease, vascular access and oncology. Its technologies are designed to help physicians treat blood clots, restore blood flow, manage vascular access and ablate targeted tissue.

The company’s portfolio includes the Auryon platform for atherectomy, which uses laser technology to treat peripheral arterial disease; the AngioVac and AlphaVac systems for removing thrombus and other unwanted material from blood vessels; and BioSentry products used to seal biopsy tracts.